Is stem cell therapy for Multiple Sclerosis FDA-approved?
The FDA patient page states that regenerative medicine therapies have not been approved in the United States to treat neurological disorders including MS. This statement does not turn every AHSCT programme into the same product; verify the legal route and standard-of-care status in the actual jurisdiction.
How stem cells are studied for Multiple Sclerosis
Multiple sclerosis is an immune-mediated central-nervous-system disorder that damages myelin, axons and neurons. Autologous haematopoietic stem-cell transplantation (AHSCT) aims to rebuild the immune system after conditioning; it is fundamentally different from an MSC infusion marketed as neural repair. Neither approach should be described as replacing lost brain tissue or universally reversing disability.
Am I a candidate? → · Multiple Sclerosis: full overview → · Multiple Sclerosis cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Multiple Sclerosis: cell-therapy evidence and registered trials
- How much does stem cell therapy for Multiple Sclerosis cost? (2026)
- Multiple Sclerosis stem cell therapy — your questions answered (2026)
- Multiple Sclerosis: cell-therapy evidence by therapy class
- MSC vs HSCT for Multiple Sclerosis: what the registries show